AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03363919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar TMS Therapy® System
Description: The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
Study NCT01367405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Description: Surgical decompression within 24 hour postinjury
Study NCT03889366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant 125 mg
Description: Single dose in the fasted state during treatment period 1,2 or 3
Study NCT03889366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Single dose in the fasted state during treatment period 1,2 or 3
Study NCT03363919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar XPLOR®
Description: NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
Study NCT04384744 — intervention group
Intervention type: DRUG
Intervention: growth hormone
Description: growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
Study NCT00415766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHCG 250ug
Description: Injection of 250 ug Ovitrelle to trigger final oocyte maturation
Study NCT00415766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uHCG 5000 IU
Description: Injection of 5000 IU Pregnyl to trigger final oocyte maturation
Study NCT00415766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uHCG 7500 IU
Description: Injection of 7500 IU Pregnyl to trigger final oocyte maturation
Study NCT00523224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogenic Cell Precursors(ACPs) or Vescell TM
Description: at least 1.5 million of ACPs per one time of treatment
Study NCT00523224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Angiogenic Cell Precusors
Description: Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
Study NCT04199013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
Study NCT04199013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
Study NCT02998970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: single oral tablet once daily.
Study NCT02998970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral tablet once daily.
Study NCT03161964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 80 Mg Oral Capsule, Extended Release
Description: Propranolol capsule over-encapsulated to match placebo for blinding
Study NCT00006695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 BID on Days -5 through -2
Study NCT00006695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 IV on Day -1
Study NCT00006695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
Study NCT00006695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I 131 tositumomab
Description: Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject
Study NCT00480740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
Study NCT00480740 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
Study NCT02382991 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3C60-NMPK
Description: 3 months with 3C60 - 10 days wash out - 1 month with NMPK
Study NCT01758432 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban
Study NCT01367405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Usual conservative treatment without surgery
Study NCT02814838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin oral capsule
Study NCT00648570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets 20 mg
Description: 20mg, single dose fasting
Study NCT00648570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lexapro® Tablets (20 mg
Description: 20mg, single dose fasting
Study NCT04226287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monterey Pneumatic Compression Device
Description: The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
Study NCT02884518 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET
Description: Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
Study NCT02884518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
Study NCT02884518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: clinical scale
Description: Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
Study NCT02884518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical scale
Description: Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
Study NCT00989404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Rotahaler placebo 10mg BID 5 days
Study NCT00989404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Rotahaler Zanamivir 10mg BID 5 days
Study NCT00989404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Diskhaler Zanamivir 10mg BID 5 days
Study NCT02687932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Study NCT02687932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT00561613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SILCS and lubricant
Study NCT00561613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS and spermicide
Study NCT02627833 — intervention group
Intervention type: OTHER
Intervention: observation
Description: Record lung function, Lung clearance index, inflammatory status
Study NCT03682939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® (meningitis B vaccine)
Description: Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
Study NCT03682939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo® (meningitis ACWY vaccine)
Description: Menveo® 0.5ml IM vaccine administered into dominant arm of participant
Study NCT03161964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule over-encapsulated to match propranolol for blinding
Study NCT01921530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Fusion
Description: The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
Study NCT01921530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Fusion
Description: In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
Study NCT03984123 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Brachial cuff, in order to achieve ischemic stimuli
Description: Standard treatment with no brachial cuff inflation
Study NCT02242565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ShangRing
Description: ShangRing device for male circumcision
Study NCT02242565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShangRing
Description: ShangRing device for male circumcision
Study NCT02261844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 1 gm po x 10 days prior to liver resection
Study NCT02261844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill daily X 10 days
Study NCT02777112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-mental health program
Description: This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
Study NCT02777112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-mental health program and job coaching
Description: This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
Study NCT02777112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
Study NCT02815449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with Low stabilizer level
Description: Meals prepared with iron fortified cube with Low stabilizer level
Study NCT02815449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with Medium stabilizer level
Description: Meals prepared with iron fortified cube with Medium stabilizer level
Study NCT02815449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with High stabilizer level
Description: Meals prepared with iron fortified cube with High stabilizer level
Study NCT01066091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mashed potatoes
Description: Mashed potatoes: Potatoes + Skim milk powder
Study NCT01066091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes + Oleic acid
Description: Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
Study NCT01066091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mashed potatoes + Palmitic acid
Description: Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
Study NCT03757975 — intervention group
Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation
Study NCT03276065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser depilation
Description: Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
Study NCT03276065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care hair depilation
Description: Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
Study NCT01190943 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02160275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (Inreda Diabetic BV)
Description: Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
Study NCT02160275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Patients' own insulin pump with fast-acting insulin analog
Study NCT03550105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
Study NCT02704780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
Study NCT03511443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hsRDT
Description: Testing highly sensitive RDT detection for low parasitemia
Study NCT01175031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manipulation of Positive Airway Pressure (PAP)
Description: Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
Study NCT01175031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation of Positive Airway Pressure (PAP)
Description: Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
Study NCT00398996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early versus intermediate versus late initiation of ART
Description: Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
Study NCT03548649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton robot training
Description: subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
Study NCT04319718 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MK-2048 High Eudragit Vaginal Film
Description: 2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)
Study NCT04319718 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MK-2048 Low Eudragit Vaginal Film
Description: 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)
Study NCT02130583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
Study NCT02130583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
Study NCT01965470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Prevention
Study NCT01965470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Study NCT04948164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan 85mg and naproxen sodium 500mg
Description: Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
Study NCT04948164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg).
Study NCT03145636 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: vBloc Maestro Rechargeable System
Description: Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
Study NCT03145636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vBloc Achieve Weight Management Program
Description: Remotely accessible web-based program to add additional support to subjects with vBloc therapy
Study NCT03145636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Weight Management (CWM) program
Description: In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
Study NCT02988024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: LY03005
Study NCT02988024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pristiq
Study NCT02516527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT00732550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single trocar cholecystectomy
Description: Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
Study NCT00732550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic cholecystectomy
Description: Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy